SA517390552B1 - مركبات بلورية مثبط امتصاص ثلاثي غير متوازن - Google Patents
مركبات بلورية مثبط امتصاص ثلاثي غير متوازنInfo
- Publication number
- SA517390552B1 SA517390552B1 SA517390552A SA517390552A SA517390552B1 SA 517390552 B1 SA517390552 B1 SA 517390552B1 SA 517390552 A SA517390552 A SA 517390552A SA 517390552 A SA517390552 A SA 517390552A SA 517390552 B1 SA517390552 B1 SA 517390552B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- reuptake inhibitor
- crystalline compounds
- triple reuptake
- triple
- same
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003174 triple reuptake inhibitor Substances 0.000 title 1
- ACVMJAJGCQUPKX-LIOBNPLQSA-N (1r,5s)-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane;hydrochloride Chemical compound Cl.C1=CC=CC2=CC([C@@]34CNC[C@H]4C3)=CC=C21 ACVMJAJGCQUPKX-LIOBNPLQSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181174P | 2015-06-17 | 2015-06-17 | |
| PCT/US2016/038256 WO2016205762A1 (en) | 2015-06-17 | 2016-06-17 | Crystalline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA517390552B1 true SA517390552B1 (ar) | 2022-04-13 |
Family
ID=57546597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA517390552A SA517390552B1 (ar) | 2015-06-17 | 2017-12-14 | مركبات بلورية مثبط امتصاص ثلاثي غير متوازن |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9708261B2 (enExample) |
| EP (3) | EP4049997A1 (enExample) |
| JP (4) | JP6896651B2 (enExample) |
| KR (1) | KR102593783B1 (enExample) |
| CN (3) | CN107921021A (enExample) |
| AU (2) | AU2016279075C1 (enExample) |
| CA (2) | CA3200692A1 (enExample) |
| CY (1) | CY1125352T1 (enExample) |
| DK (1) | DK3597189T3 (enExample) |
| ES (1) | ES2922158T3 (enExample) |
| HK (1) | HK1247125A1 (enExample) |
| HR (1) | HRP20220829T1 (enExample) |
| HU (1) | HUE059348T2 (enExample) |
| LT (1) | LT3597189T (enExample) |
| MX (2) | MX387591B (enExample) |
| MY (1) | MY194868A (enExample) |
| NZ (2) | NZ776973A (enExample) |
| PH (1) | PH12017502324A1 (enExample) |
| PL (1) | PL3597189T3 (enExample) |
| PT (1) | PT3597189T (enExample) |
| SA (1) | SA517390552B1 (enExample) |
| SG (1) | SG10201911417PA (enExample) |
| SI (1) | SI3597189T1 (enExample) |
| TW (1) | TWI751998B (enExample) |
| WO (1) | WO2016205762A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101272781A (zh) | 2005-07-27 | 2008-09-24 | 多夫药品公司 | 新的1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途 |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| US20160303077A1 (en) | 2013-12-09 | 2016-10-20 | Neurovance, Inc. | Novel compositions |
| CN107921021A (zh) | 2015-06-17 | 2018-04-17 | 大塚制药美国公司 | 结晶化合物 |
| CN111417624B (zh) * | 2017-12-11 | 2022-03-25 | 苏州科睿思制药有限公司 | Eb-1020的晶型及其制备方法和用途 |
| WO2021075494A1 (ja) | 2019-10-16 | 2021-04-22 | 大塚製薬株式会社 | センタナファジンの製造方法 |
| WO2022256215A1 (en) | 2021-05-31 | 2022-12-08 | Teva Pharmaceuticals International Gmbh | Solid state form of centanafadine hcl and process for preparation thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094799B2 (en) | 2002-11-08 | 2006-08-22 | Dov Pharmaceutical, Inc. | Polymorphs of bicifadine hydrochloride |
| EP1740593B1 (en) | 2004-04-19 | 2016-04-06 | KRKA, tovarna zdravil, d.d., Novo mesto | Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i |
| US20070043100A1 (en) | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
| ZA200701570B (en) | 2004-08-18 | 2008-08-27 | Dov Pharmaceutical Inc | Novel polymorphs of azabicyclohexane |
| US20070082939A1 (en) | 2005-07-26 | 2007-04-12 | Lippa Arnold S | Methods and compositions for the treatment of neuropathies and related disorders |
| CN101272781A (zh) | 2005-07-27 | 2008-09-24 | 多夫药品公司 | 新的1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途 |
| US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| US20080058535A1 (en) * | 2006-07-25 | 2008-03-06 | Zhengming Chen | Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes |
| US8576985B2 (en) | 2009-09-01 | 2013-11-05 | Aptuit (West Lafayette) Llc | Methods for indexing solid forms of compounds |
| CN103476770B (zh) * | 2010-11-25 | 2017-02-15 | 拉蒂欧制药有限责任公司 | 阿法替尼盐和多晶型物 |
| HRP20200424T1 (hr) | 2011-07-30 | 2020-09-04 | Otsuka America Pharmaceutical, Inc. | Uporaba (1r,5s)-(+)-1-(naftalen-2-il)-3-azabiciklo(3.1.0)heksana u liječenju uvjeta koji su pod utjecajem monoaminskih neurotransmitera |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| US20140228421A1 (en) | 2011-09-07 | 2014-08-14 | Anthony McKinney | Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters |
| US20160303077A1 (en) | 2013-12-09 | 2016-10-20 | Neurovance, Inc. | Novel compositions |
| CN107921021A (zh) | 2015-06-17 | 2018-04-17 | 大塚制药美国公司 | 结晶化合物 |
-
2016
- 2016-06-17 CN CN201680035027.1A patent/CN107921021A/zh active Pending
- 2016-06-17 EP EP22164478.4A patent/EP4049997A1/en active Pending
- 2016-06-17 KR KR1020187001083A patent/KR102593783B1/ko active Active
- 2016-06-17 NZ NZ776973A patent/NZ776973A/en unknown
- 2016-06-17 MY MYPI2017704811A patent/MY194868A/en unknown
- 2016-06-17 NZ NZ739044A patent/NZ739044A/en unknown
- 2016-06-17 EP EP19196556.5A patent/EP3597189B1/en active Active
- 2016-06-17 US US15/186,415 patent/US9708261B2/en active Active
- 2016-06-17 CA CA3200692A patent/CA3200692A1/en active Pending
- 2016-06-17 PL PL19196556.5T patent/PL3597189T3/pl unknown
- 2016-06-17 PT PT191965565T patent/PT3597189T/pt unknown
- 2016-06-17 LT LTEP19196556.5T patent/LT3597189T/lt unknown
- 2016-06-17 SI SI201631552T patent/SI3597189T1/sl unknown
- 2016-06-17 MX MX2017016430A patent/MX387591B/es unknown
- 2016-06-17 SG SG10201911417PA patent/SG10201911417PA/en unknown
- 2016-06-17 ES ES19196556T patent/ES2922158T3/es active Active
- 2016-06-17 DK DK19196556.5T patent/DK3597189T3/da active
- 2016-06-17 HK HK18106861.3A patent/HK1247125A1/zh unknown
- 2016-06-17 HU HUE19196556A patent/HUE059348T2/hu unknown
- 2016-06-17 CA CA2989431A patent/CA2989431C/en active Active
- 2016-06-17 JP JP2017565236A patent/JP6896651B2/ja active Active
- 2016-06-17 CN CN202310848120.6A patent/CN117088802A/zh active Pending
- 2016-06-17 EP EP16812592.0A patent/EP3310352A4/en not_active Ceased
- 2016-06-17 AU AU2016279075A patent/AU2016279075C1/en active Active
- 2016-06-17 WO PCT/US2016/038256 patent/WO2016205762A1/en not_active Ceased
- 2016-06-17 CN CN202310843667.7A patent/CN117466800A/zh active Pending
- 2016-06-17 HR HRP20220829TT patent/HRP20220829T1/hr unknown
- 2016-12-21 TW TW105142467A patent/TWI751998B/zh active
-
2017
- 2017-06-01 US US15/611,580 patent/US9856217B2/en active Active
- 2017-11-21 US US15/820,241 patent/US10280141B2/en active Active
- 2017-12-14 SA SA517390552A patent/SA517390552B1/ar unknown
- 2017-12-15 MX MX2020009949A patent/MX2020009949A/es unknown
- 2017-12-15 PH PH12017502324A patent/PH12017502324A1/en unknown
-
2019
- 2019-03-11 US US16/298,179 patent/US10800740B2/en active Active
-
2020
- 2020-08-14 US US16/993,648 patent/US11299458B2/en active Active
-
2021
- 2021-01-19 AU AU2021200314A patent/AU2021200314B2/en active Active
- 2021-06-09 JP JP2021096354A patent/JP7244575B2/ja active Active
-
2022
- 2022-07-11 CY CY20221100470T patent/CY1125352T1/el unknown
-
2023
- 2023-03-09 JP JP2023036730A patent/JP7583851B2/ja active Active
-
2024
- 2024-11-01 JP JP2024192608A patent/JP2025022896A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA517390552B1 (ar) | مركبات بلورية مثبط امتصاص ثلاثي غير متوازن | |
| AU2019264537A1 (en) | Beta-lactamase inhibitors | |
| GEP20207147B (en) | Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors | |
| PH12019550235A1 (en) | Kinase inhibitors and uses thereof | |
| NZ739676A (en) | Heteroaryl compounds as irak inhibitors and uses thereof | |
| IL282460A (en) | The compound 2-azabicyclohexane as a JAK inhibitor | |
| MX370450B (es) | Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica. | |
| EP4327809A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2016003843A (es) | Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. | |
| UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
| PH12017502051A1 (en) | TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | |
| MX2015012111A (es) | Moduladores de ship1 y métodos relacionados con éstos. | |
| AU2014324961A8 (en) | Highly potent glucocorticoids | |
| PH12016501472B1 (en) | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use | |
| TW201613934A (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
| PH12017500459A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| EA201892235A1 (ru) | Гранулированная композиция для перорального применения | |
| MX2019012665A (es) | Compuestos organicos. | |
| MA39877A (fr) | Formes solides d'un composé pharmaceutiquement actif | |
| MX2017016638A (es) | Compuestos organolepticos novedosos. | |
| IN2013MU03308A (enExample) | ||
| HK1232076A1 (zh) | 用於取代的1-苄基-3-(1-(异恶唑-4-基甲基)-1h-吡唑-4-基)咪唑烷-2，4-二酮的合成的改进方法 | |
| JO3639B1 (ar) | صورة متعددة الشكل جديدة لـ n-[2-(6-فلورو-1h-إندول-3-يل)إيثيل]-3-(2،2،3،3-تترا فلورو بروبوكسي)بنزيل أمين هيدروكلوريد | |
| MX2015005523A (es) | Novedoso compuesto organoleptico. |